FindTrial
Sign In

To evaluate levobupivacaine and bupivacaine in paediatric patient in below umbilical surgeries for post operative pain analgesia in caudal block.

Clinical evaluation of caudal levobupivacaine and bupivacaine for postoperative pain management in paediatric infraumblical surgeries.

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2023/06/053764
Enrollment
60
Registered
2023-06-12
Start date
Unknown
Completion date
Unknown
Last updated
2023-06-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: N471- Phimosis Health Condition 2: K624- Stenosis of anus and rectum Health Condition 3: K409- Unilateral inguinal hernia, without obstruction or gangrene

Interventions

Intervention1: Levobupivacaine: Levobupivacaine 0.25% for caudal analgesia for infraumblical surgeries in children. Control Intervention1: Bupivacaine: Bupivacaine 0.25% for caudal analgesia for infra

Sponsors

department of anaesthesiology gandhi medical college bhopal
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. age group 2 to 5 years of either sex. 2. patients of ASA grade I & II. 3. all paediatric patients scheduled for elective infraumblical surgeries.

Exclusion criteria

Exclusion criteria: 1. parents refusal or not giving consent. 2. seizure disorder. 3. ASA grade III,IV,V.

Design outcomes

Primary

MeasureTime frame
efficacy of bupivacaine 0.25% and levobupivacaine 0.25% in caudal block for post operative pain analgesia.Timepoint: Post Operatively pain score after 15min, 30 min, 60min,120min—

Secondary

MeasureTime frame
hemodynamic changes, requirement of rescue analgesia and adverse effect.Timepoint: at 1 min , 5 min, 10 min, 15 min, 30 min—

Countries

India

Contacts

Public ContactDr shashi kumari

Gandhi medical college

drsurmi@rediffmail.com9826757745

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026